Anti-VEGF: the evidence
This article from our recent issue on non-communicable eye diseases summarises the current Cochrane reviews on the effects of anti-VEGF treatment for age-related macular degeneration (AMD), diabetic macular oedema and safety.
The article looks at the evidence on:
- effects of anti-VEGF on vision
- adverse events
- systemic safety of ranibizumab and bevacizumab
- future research directions